Blockchain Registration Transaction Record

NanoViricides' NV-387 Shows Safety in Juvenile Mice, Paving Way for Pediatric Trials

NanoViricides' NV-387 shows positive safety in juvenile mice, supporting pediatric trials for Ebola, Mpox, and measles. The broad-spectrum antiviral advances.

The positive juvenile toxicity results for NV-387 are a critical step toward expanding this broad-spectrum antiviral into pediatric populations, where safe treatment options for Ebola, Mpox, and measles are urgently needed. If NV-387 proves effective in children, it could provide a much-needed weapon against outbreaks that disproportionately affect vulnerable young patients. For NanoViricides, these findings strengthen the case for partnerships and nondilutive funding, which are essential given the company's going-concern warning. The news matters because it signals progress in developing a platform that could address multiple deadly viruses with a single drug, potentially transforming how we respond to future epidemics.